✦ LIBER ✦

Serum PAI-1 is a novel predictor for response to pegylated interferon-α-2b plus ribavirin therapy in chronic hepatitis C virus infection

✍ Scribed by D. Miki; W. Ohishi; H. Ochi; C. N. Hayes; H. Abe; M. Tsuge; M. Imamura; N. Kamatani; Y. Nakamura; K. Chayama

Book ID: 108886652
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 114 KB
Volume: 19
Category: Article
ISSN: 1352-0504
DOI: 10.1111/j.1365-2893.2011.01516.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized trial comparing pegylated int

Randomized trial comparing pegylated interferon α-2b versus pegylated interferon α-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients

✍ Montserrat Laguno; Carmen Cifuentes; Javier Murillas; Sergio Veloso; Maria Larro 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 370 KB

Adverse skin reactions due to pegylated

Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus

✍ Yuki HASHIMOTO; Hiromi KANTO; Masatoshi ITOH 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 1023 KB

Mutations in the interferon sensitivity

Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection

✍ Mina Nakagawa; Naoya Sakamoto; Mayumi Ueyama; Kaoru Mogushi; Satoshi Nagaie; Yas 📂 Article 📅 2010 🏛 Springer Japan 🌐 English ⚖ 266 KB

Repeated episodes of fixed eruption 3 mo

Repeated episodes of fixed eruption 3 months after discontinuing pegylated interferon-α-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection

✍ M. Sato; H. Sueki; M. Iijima 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 253 KB

Ribavirin pharmacokinetics and interleuk

Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4

✍ Antonio D'Avolio; Alessia Ciancio; Marco Siccardi; Lorena Baietto; Marco Simiele 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 1 views

We read with great interest the recent report by Li et al. 1 analyzing the correlation between the clusters of differentiation 24 (CD24) polymorphism and risk of chronic hepatitis B virus (HBV) infection. In their study, the CD24 P170 T allele (thymidine at position 170) was correlated with a strong

Variants in interferon-alpha pathway gen

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial

✍ Tania Mara Welzel; Timothy R. Morgan; Herbert L. Bonkovsky; Deepa Naishadham; Ru 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB 👁 2 views

Combination treatment with pegylated-interferon-alpha (PEG IFN-␣) and ribavirin, the current recommended therapy for chronic hepatitis C virus (HCV) infection, results in a sustained virological response (SVR) in only about half of patients. Because genes involved in the interferon-alpha pathway may